S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
ASX:ANP

Antisense Therapeutics (ANP) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1.32 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
4.58%
Price Target
N/A
ANP stock logo

About Antisense Therapeutics Stock (ASX:ANP)

Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.

ANP Stock News Headlines

Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
ANP's Aimal Wali rejects polls results
ECP allocates 'lantern' symbol to ANP
Some Confidence Is Lacking In Anpario plc's (LON:ANP) P/E
MQM-P, ANP join forces for polls
Kymera Therapeutics Inc Ordinary Shares
See More Headlines
Receive ANP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Antisense Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2019
Today
4/18/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Net Income
$-11,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.58 million
Book Value
A$0.01 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.06
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

ANP Stock Analysis - Frequently Asked Questions

How were Antisense Therapeutics' earnings last quarter?

Antisense Therapeutics Limited (ASX:ANP) issued its earnings results on Wednesday, February, 27th. The company reported $0.00 EPS for the quarter.

What other stocks do shareholders of Antisense Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Antisense Therapeutics investors own include Tocagen (TOCA), Miragen Therapeutics (MGEN), Iovance Biotherapeutics (IOVA), Genocea Biosciences (GNCA), Capricor Therapeutics (CAPR) and Applied DNA Sciences (APDN).

This page (ASX:ANP) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners